N0539 phase II trial of fulvestrant and bevacizumab in patients with metastatic breast cancer previously treated with an aromatase inhibitor: a North Central Cancer Treatment Group...

Por Tan, W. W., Dueck, A. C., Flynn, P., Steen, P., Anderson, D., Rowland, K., Northfelt, D., Perez, E. A.
Publicado em 2013

Optimization of DSC MRI Echo Times for CBV Measurements Using Error Analysis in a Pilot Study of High-Grade Gliomas

Por Bell, L.C., Does, M.D., Stokes, A.M., Baxter, L.C., Schmainda, K.M., Dueck, A.C., Quarles, C.C.
Publicado no AJNR Am J Neuroradiol (2017)

Longitudinal modeling of frontal cognition in APOE ε4 homozygotes, heterozygotes, and noncarriers

Por Caselli, R.J., Dueck, A.C., Locke, D.E.C., Hoffman-Snyder, C.R., Woodruff, B.K., Rapcsak, S.Z., Reiman, E.M.
Publicado em 2011

Endpoint comparison for bone mineral density measurements in North Central Cancer Treatment Group cancer clinical trials N02C1 and N03CC (Alliance)

Por Dueck, A. C., Singh, J., Atherton, P., Liu, H., Novotny, P., Hines, S., Loprinzi, C. L., Perez, E. A., Tan, A., Burger, K., Zhao, X., Diekmann, B., Sloan, J. A.
Publicado no Osteoporos Int (2015)

A phase III randomized, double-blind, placebo-controlled trial of gabapentin in the management of hot flashes in men (N00CB)

Por Loprinzi, C. L., Dueck, A. C., Khoyratty, B. S., Barton, D. L., Jafar, S., Rowland, K. M., Atherton, P. J., Marsa, G. W., Knutson, W. H., Bearden, J. D., Kottschade, L., Fitch, T. R.
Publicado em 2009

North Central Cancer Treatment Group (NCCTG) N0432: phase II trial of docetaxel with capecitabine and bevacizumab as first-line chemotherapy for patients with metastatic breast can...

Por Perez, E. A., Hillman, D. W., Dentchev, T., Le-Lindqwister, N. A., Geeraerts, L. H., Fitch, T. R., Liu, H., Graham, D. L., Kahanic, S. P., Gross, H. M., Patel, T. A., Palmieri, F. M., Dueck, A. C.
Publicado em 2010

Cerebrovascular risk factors and preclinical memory decline in healthy APOE ε4 homozygotes

Por Caselli, R.J., Dueck, A.C., Locke, D.E.C., Sabbagh, M.N., Ahern, G.L., Rapcsak, S.Z., Baxter, L.C., Yaari, R., Woodruff, B.K., Hoffman-Snyder, C., Rademakers, R., Findley, S., Reiman, E.M.
Publicado em 2011

EGFR expression is associated with decreased benefit from trastuzumab in the NCCTG N9831 (Alliance) trial

Por Cheng, H, Ballman, K, Vassilakopoulou, M, Dueck, A C, Reinholz, M M, Tenner, K, Gralow, J, Hudis, C, Davidson, N E, Fountzilas, G, McCullough, A E, Chen, B, Psyrri, A, Rimm, D L, Perez, E A
Publicado no Br J Cancer (2014)

Impact of Software Modeling on the Accuracy of Perfusion MRI in Glioma

Por Hu, L.S., Kelm, Z., Korfiatis, P., Dueck, A.C., Elrod, C., Ellingson, B.M., Kaufmann, T.J., Eschbacher, J.M., Karis, J.P., Smith, K., Nakaji, P., Brinkman, D., Pafundi, D., Baxter, L.C., Erickson, B.J.
Publicado no AJNR Am J Neuroradiol (2015)

Optimized Preload Leakage-Correction Methods to Improve the Diagnostic Accuracy of Dynamic Susceptibility-Weighted Contrast-Enhanced Perfusion MR Imaging in Posttreatment Gliomas

Por Hu, L.S., Baxter, L.C., Pinnaduwage, D.S., Paine, T.L., Karis, J.P., Feuerstein, B.G., Schmainda, K.M., Dueck, A.C., Debbins, J., Smith, K.A., Nakaji, P., Eschbacher, J.M., Coons, S.W., Heiserman, J.E.
Publicado no AJNR Am J Neuroradiol (2010)

Soluble HER2 (sHER2) levels in HER2-positive breast cancer patients receiving chemotherapy ± trastuzumab: Results from the NCCTG adjuvant trial N9831

Por Moreno-Aspitia, A., Hillman, D. W., Dyar, S. H., Tenner, K. S., Gralow, J., Kaufman, P. A., Davidson, N. E., Lafky, J. M., Reinholz, M. M., Lingle, W. L., Kutteh, L. A., Carney, W. P., Dueck, A. C., Perez, E. A.
Publicado em 2013